SOURCES SOUGHT
B -- Test the efficacy and potency of two compounds in reducing induced fibrosis in validated 3D bioprinted liver tissue models
- Notice Date
- 4/9/2018
- Notice Type
- Sources Sought
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800153
- Point of Contact
- Stuart G. Kern, Phone: 3014023334
- E-Mail Address
-
stuart.kern@nih.gov
(stuart.kern@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description: This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information and availability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government's requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: Alternative cell-based assay models of disease that are more predictive of efficacy and toxicity of compounds in clinic are being developed to help prioritize compounds for in vivo testing, reduce use of animal testing, and possibly reduce time to clinic and cost of drug development. Manufactured 3D tissue models that mimic a human tissue in cell composition and architecture, and produced with human primary or iPSC-derived cells are now available for some tissues, including liver. 3D liver tissue models of fibrosis have been described in recent worldwide publications and provide a unique opportunity to test compounds for their ability to reduced induced fibrosis in a tissue model that it is possibly more predictive of activity in clinic. Purpose and Objectives: The contractor shall test compounds for modulation TGFβ induced fibrosis in validated 3D bioprinted human liver tissue that include Kupffer cells. Project requirements: Contractor shall test two compounds provided by the Government in at least three doses in validated 3D liver tissue models of induced liver fibrosis: •The 3D liver tissue models of fibrosis must be 3D bioprinted. •3D liver tissue models should include human primary hepatocytes, kupffer cells, liver endothelial cells, and liver stellate cells. •Published reports demonstrating assay performance, validation and pharmacological qualification should be provided. •TGF-β induction of fibrosis for 7 days or more and be measured by IHC using pro-fibrotic markers including aSMA and collagen I, and CD68. •Additional makers that provide information on the effects of compounds on the 3D liver tissue will be positively considered. •At least one assay/marker of cell viability will also be included in the test •Compounds will be tested in N=4, and at least at three different concentrations •A positive control compound treatment will be done in parallel with the test compounds All data obtained from the tissues, processed IHC tissue slides, and unprocessed/unused tissue blocks and slides will be provided to NCATS for potential additional analysis at the end of the study. Anticipated period of performance: The contractors will be required to deliver the results in a fully detailed report within 60 days from receipt of compounds from NCATS. Capability statement /information sought. Responses to this notice must include sufficient information to establish the interested parties' bona-fide capabilities to accomplish the project requirements. In addition, respondents may include information regarding their (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code, and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. This Notice is posted by the Office of Acquisitions, National Institute on Drug Abuse, NCATS Section. The response must be submitted to Stuart Kern, Contract Specialist, at stuart.kern@nih.gov. Facsimile responses are NOT accepted. Responses must be received on or before 11:00 a.m., Eastern time, on Friday, April 13, 2018. "Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800153/listing.html)
- Place of Performance
- Address: National Center for Advancing Translational Sciences, 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN04882741-W 20180411/180409230654-11ac077f407867ba0a1d3cf11188b23b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |